Prior to Friday's decision, the Obesity Action Coalition along with 80 other organizations sent a letter to HHS Secretary ...

CMS has released its final rule for Medicare Advantage and Part D for 2026, introducing several regulatory changes aimed at improving care coordination and beneficiary protections. While the rule ...

Popular weight loss drugs may do more than curb appetite — they may also help reduce the risk of dementia, according to new research.

Medicare Advantage updates while halting proposed anti-obesity drug coverage, impacting millions of potential beneficiaries.

A federal commission is calling for $15 billion in new financing to reinforce U.S. biotech leadership amid competition from ...

The Trump administration reversed a Biden-era proposal for Medicare coverage of anti-obesity treatments. But on Monday, HHS ...

As the popularity of weight loss medications like Ozempic®, Wegovy®, and Mounjaro™ continues to surge, Greenberg Cosmetic Surgery and Dermatology is proud to announce the launch of the Ozempic ...

Pennsylvania and Connecticut are looking to tighten guidelines for people who want to use GLP-1s solely for weight loss.

India’s obesity crisis fuels a $2.6 bn drug race as pharma firms rush to launch affordable semaglutide generics, aiming to ...

The Trump administration has decided not to expand Medicare and Medicaid coverage for popular obesity drugs, blocking a Biden ...

In November last year, the Biden administration proposed a new rule that would allow drugs like Wegovy and Zepbound to be ...